Could a new neuroprotective drug improve recovery even when given as long as 48 hours after an ischemic stroke?

This episode reviews a randomized phase 3 trial suggesting that loberamisal may improve functional recovery following acute ischemic stroke; a SELECT trial analysis examining the efficacy and safety of semaglutide across different levels of frailty; and a CDC investigation of deaths and serious adverse events following ceftriaxone injections that highlights how severe anaphylaxis can occur without classic skin findings.